Moderna shares decline, RSV vaccine efficacy lags behind competitors
Moderna Inc (NASDAQ: MRNA) shares dropped 11% on Wednesday after revealing that its RSV vaccine, mResvia, demonstrated 50% efficacy...
Moderna Inc (NASDAQ: MRNA) shares dropped 11% on Wednesday after revealing that its RSV vaccine, mResvia, demonstrated 50% efficacy...